Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ann Arbor staging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Ann Arbor staging. Displaying page 1 of 1.
    EudraCT Number: 2021-000362-15 Sponsor Protocol Number: FORTplus Start Date*: 2022-03-24
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
    Full Title: Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody
    Medical condition: nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029603 Non-Hodgkin's lymphoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001363-12 Sponsor Protocol Number: TRIANGLE Start Date*: 2016-03-24
    Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III
    Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
    Medical condition: Generalized mantle cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026805 Mantle cell lymphoma stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026804 Mantle cell lymphoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002059-89 Sponsor Protocol Number: GAZAI Start Date*: 2017-11-02
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg
    Full Title: Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro
    Medical condition: nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029602 Non-Hodgkin's lymphoma stage I PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029603 Non-Hodgkin's lymphoma stage II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001404-38 Sponsor Protocol Number: FIL_GEMRO Start Date*: 2012-07-12
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Medical condition: Relapsed/refractory peripheral T-cell lymphoma patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005542-11 Sponsor Protocol Number: 20130109 Start Date*: 2014-10-14
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
    Medical condition: CD20 positive B-cell non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) RO (Completed) IT (Completed) ES (Completed) FR (Completed) BG (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005818-10 Sponsor Protocol Number: AGMT_MALT-2 Start Date*: 2012-05-02
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002935-30 Sponsor Protocol Number: 20-01434 Start Date*: 2023-01-20
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:47:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA